drugset / Trial / NCT06014255
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Phase 2
Recruiting
219 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MacroGenics · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Timeline
- Start
- 2024-02-16
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoblituzumab | Monoclonal antibody | 15 mg/kg | Intravenous |